English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Heart failure is one of the most common causes of death and disability encountered in clinical practice. Recently animal studies and clinical trials demonstrated additional benefits following the addition of an Angiotensin receptor blocker to existing Angiotensin converting enzyme inhibitor. It was a comparative randomized study performed on 100 patients admitted in cardiology Department, Government General Hospital, and Guntur. The study comprised of 6 weeks period for each patient .50 patients were under Enalapril and 50 patients were under combination of Enalapril and Losartan. Before and after 6 weeks, Blood studie ,E.C.G ,Chest x ray ,2D echo were done .Patients were monitored for relief of symptoms ,change in blood pressure and adverse effects. Results were tabulated, unpaired students't' test was done and p values were calculated .Results were shown graphically also.The combination therapy improved the symptoms ,ejection fraction (P < 0.001 ) and increased serum potassium significantly. (P < 0.05) . So,the present study showed that combination therapy (Enalapril plus losartan) had better efficacy than Enalapril alone in the management of congestive cardiac failure.

Comparative study of efficacy of Enalapril and Enalapril with Losartan in the management of Heart Failure